Loading...
Indian Pharmaceutical Exporter · Respiratory & OTC Specialist · $270.8K Total Trade · DGFT Verified
Arco Pharma Private Limited is an Indian pharmaceutical exporter with a total trade value of $270.8K across 2 products in 2 therapeutic categories. Based on 23 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Aminophylline ($248.0K), Niacin ($22.8K), .
Arco Pharma Private Limited, incorporated on March 22, 1983, is a private unlisted company based in Mumbai, Maharashtra, India. The company is classified under the Corporate Identification Number (CIN) U24230MH1983PTC029602 and is registered at the Registrar of Companies, Mumbai. Its authorized share capital is ₹10,000,000, with a paid-up capital of ₹5,000,000. The registered office is located at 60/70, Ranvir Building, 2nd Floor, Room No.15, Princess Street, Mumbai, Maharashtra, 400002.
The company specializes in the manufacturing of pharmaceuticals, medicinal chemicals, and botanical products. As of March 29, 2024, Arco Pharma employed 11 individuals. The ownership structure is predominantly held by promoters, with 92.83% shareholding, while the public holds 4.10%, and others account for 3.07%.
Arco Pharma Private Limited operates across 2 therapeutic categories, with Respiratory & OTC (91.6%), Lipid & Metabolism (8.4%), representing the largest segments by export value. The portfolio is concentrated — the top 5 products account for 100% of total exports.
Respiratory & OTC
1 products · 91.6% · $248.0K
Lipid & Metabolism
1 products · 8.4% · $22.8K
Arco Pharma Private Limited exports 2 pharmaceutical products across 2 therapeutic categories.
| # | Product | Category | Export Value | Shipments | Market Share | Rank |
|---|---|---|---|---|---|---|
| 1 | Aminophylline | Respiratory & OTC | $248.0K | 19 | 4.2% |
Headquarters, ownership, manufacturing facilities, and key leadership
Arco Pharma Private Limited, incorporated on March 22, 1983, is a private unlisted company based in Mumbai, Maharashtra, India. The company is classified under the Corporate Identification Number (CIN) U24230MH1983PTC029602 and is registered at the Registrar of Companies, Mumbai. Its authorized share capital is ₹10,000,000, with a paid-up capital of ₹5,000,000. The registered office is located at 60/70, Ranvir Building, 2nd Floor, Room No.15, Princess Street, Mumbai, Maharashtra, 400002.
The company specializes in the manufacturing of pharmaceuticals, medicinal chemicals, and botanical products. As of March 29, 2024, Arco Pharma employed 11 individuals. The ownership structure is predominantly held by promoters, with 92.83% shareholding, while the public holds 4.10%, and others account for 3.07%.
Arco Pharma Private Limited operates manufacturing facilities in Mumbai, Maharashtra. Specific details regarding plant locations, capacities, and specializations are not publicly disclosed. The company's focus is on the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. However, comprehensive information about the manufacturing processes and capacities is not readily available.
| 2 |
| 2 | Niacin | Lipid & Metabolism | $22.8K | 4 | 0.6% | 10 |
Arco Pharma Private Limited exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $270.8K. The top category is Respiratory & OTC (91.6% of portfolio), followed by Lipid & Metabolism (8.4%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.
Shipment-level records, pricing & buyer contacts for Arco Pharma Private Limited.
Request DemoThe key executives of Arco Pharma Private Limited include:
Information regarding the roles of Chief Executive Officer (CEO) or Chief Financial Officer (CFO) is not publicly available.
Regulated market presence, emerging market penetration, and geographic strategy
Arco Pharma Private Limited's export activities, as per TransData Nexus proprietary trade data, include:
Specific details regarding regulatory filings, approvals, and market access status in the United States, European Union, United Kingdom, Australia, and Japan are not publicly disclosed. The company's export activities are primarily focused on the Respiratory & OTC and Lipid & Metabolism therapeutic categories.
Arco Pharma Private Limited's export data indicates a focus on the Respiratory & OTC and Lipid & Metabolism therapeutic categories. Specific information regarding the company's penetration into African, Latin American, and Southeast Asian markets, as well as WHO prequalification status, is not publicly available.
Arco Pharma Private Limited's export activities are concentrated in the Respiratory & OTC and Lipid & Metabolism therapeutic categories, with Aminophylline and Niacin being the top exported products. The company's portfolio concentration is 100% on these top 5 products, indicating a focused product strategy. However, specific details regarding geographic diversification, concentration risk, and strategic direction are not publicly disclosed.
FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record
Specific information regarding Arco Pharma Private Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history is not publicly available. The company's export data does not provide insights into its presence in the U.S. market.
Details regarding Arco Pharma Private Limited's WHO prequalification, EU Good Manufacturing Practice (GMP) certificates, and European Directorate for the Quality of Medicines & HealthCare (EDQM) status are not publicly available. The company's export data does not indicate compliance with these international standards.
Specific information regarding Arco Pharma Private Limited's Central Drugs Standard Control Organisation (CDSCO) manufacturing licenses, state drug controller approvals, and export No Objection Certificates (NOCs) is not publicly available. The company's export data does not provide insights into its compliance with Indian regulatory requirements.
There are no publicly available records of Form 483 observations, warning letters, or import alerts issued to Arco Pharma Private Limited. The company's export data does not indicate any recent regulatory actions.
Market share comparison, key differentiators, and strategic analysis
Arco Pharma Private Limited operates in the pharmaceutical manufacturing sector, focusing on finished pharmaceutical formulations in the Respiratory & OTC and Lipid & Metabolism therapeutic categories. Specific information regarding its top competitors, market share comparison, and head-to-head analysis is not publicly available.
Arco Pharma Private Limited's key differentiators include its focus on finished pharmaceutical formulations in the Respiratory & OTC and Lipid & Metabolism therapeutic categories, with Aminophylline and Niacin being the top exported products. The company's portfolio concentration on these top 5 products indicates a specialized product strategy. However, specific details regarding unique strengths, competitive advantages, and product portfolio distinctions are not publicly disclosed.
Arco Pharma Private Limited's strategic direction appears to be focused on the manufacturing and export of finished pharmaceutical formulations in the Respiratory & OTC and Lipid & Metabolism therapeutic categories. The company's portfolio concentration on its top 5 products suggests a specialized approach. However, specific information regarding its current strategic direction, such as emphasis on generics, specialty drugs, biosimilars, or Contract Development and Manufacturing Organization (CDMO) services, as well as future outlook, is not publicly available.
Track record assessment, certifications to verify, and pre-order checks
Arco Pharma Private Limited's export data indicates a focus on the Respiratory & OTC and Lipid & Metabolism therapeutic categories, with Aminophylline and Niacin being the top exported products. The company's portfolio concentration on these top 5 products suggests a specialized product strategy. However, specific information regarding the company's overall track record, export volume and consistency, and reliability indicators is not publicly available.
Importers considering Arco Pharma Private Limited as a supplier should verify the following certifications:
Verification can be conducted through official regulatory bodies' websites or by requesting documentation directly from the supplier.
Importers should undertake the following steps to ensure a comprehensive evaluation of Arco Pharma Private Limited:
Red flags to watch for include expired or invalid certifications, inconsistent financial records, and a history of regulatory non-compliance. Recommended pre-order checks involve requesting up-to-date certifications, recent financial statements, and references from previous clients.
Arco Pharma Private Limited exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Aminophylline ($248.0K), Niacin ($22.8K). Total export value is $270.8K.
Arco Pharma Private Limited's total pharmaceutical export value is $270.8K, based on 23 verified shipments recorded in Indian Customs (DGFT) data.
Arco Pharma Private Limited exports across 2 therapeutic categories. The largest are Respiratory & OTC (91.6%, 1 products), Lipid & Metabolism (8.4%, 1 products).
Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Verify manufacturer licensing, GMP certification, and export registration with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
2 Products Tracked
2 therapeutic categories
Expert-Reviewed
By pharmaceutical trade specialists
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.